Lyra Therapeutics (LYRA) 10 Mar 212020 Q4 Earnings call transcript

Welcome to the Lyra Therapeutics Fourth Quarter and End Year 2020 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.

Following management's prepare remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this call is being recorded today March 9, 2021. I would now like to turn the conference call over to Laurence Watts, Managing Director at Gilmartin Group. ahead. go Please,

Terry. Thank you,

Senior on released President the Financial Lyra us quarter XX, Noyes. Kern; today Don and December Commercial Market ended Development, results call Chief Executive for are Corinne and Rob and Officer, Chief today, Chief Therapeutics President Officer, of Elsey; Strategy Lyra Joining Early Medical from Vice financial Maria Officer, fourth XXXX. Palasis; the

company's Lyra's be distribution received this news or added If releases, to to go at relations the can to you the not have found please list you release, future website, receive investor -- be www.lyratherapeutics.com. to section which of

significant and of as company to and materially and expectations. During forward-looking the that, planned that Maria from to to place forward-looking report statements events over results the statements, and candidates, undue results reliance timing -- on any expectations the or obligation of business duty Lyra's statements operations. to inherently include a current be turn its undertakes and Lyra future make are forward-looking could Maria? or of XXXX, uncertainties. now risk financial CEO based not in will you and filed the to call I new company's conference XXXX. forward-looking With and update cautions anticipated including involves events Therapeutics. result guidance These as results form no changes describes these actual these in today, Palasis, in will statements call cause uncertainties. development of and titled information, forward-looking factors risks the company's result of strategy XX-K the different management section the on those the such annual statements, product factors differ company's Lyra's March and statements X, on related could Factors risks from a for clinical statements, the

and the culminating December, bodes welcome, was in full clinical XX-patient fourth And LANTERN and Lyra, our Phase conference X results our future this to year XXXX the of study, Lyra's exciting everyone results quarter in pandemic. believe call. XXXX release well of in Therapeutics financial at an X you, our Thank Phase Laurence. year trial programs. enrollment in ongoing for the global both We pivotal enrollment pharmacokinetic and COVID-XX despite completion successful

Otolaryngology by I turn recent our of remind has chronic key as and Medical Society. me He a Officer. is made. rhinosinusitis. Otolaryngologist LANTERN the that of Kern, appointed who has in the let Lyra joined a the expert world past results, Chair University some Rob Before a and Dr. Rhinologic to is been appointments Recently, leading American renowned we immediate of at president you Robert Northwestern Chief were

options and look for treatment for Nancy to the We team surgeon. to phase on ENT and head a Nancy we enormous As the with forward Board knows we CRS. the expanded experience of he neck fourth rhinosinusitis, as of of firsthand through also Snyderman. Otolaryngologist, need for new join certified Directors extensive were otolaryngologist a or development he patients the and be quarter, LYR-XXX. And overseeing next LYR-XXX In clinical delighted chronic are practicing will appointment leaning her pleased have board Dr. and our our

to failed just Having the half now therapy. failing billion with are ex-US of United Lyra best-in-class who is States. for for market which know, currently be to medical each patients LYR-XXX modifying disease designed the in when has CRS annually, demonstrated, treatment are there management. considered. opportunity and the patients focus in greater even estimated you and markets X underserved LYR-XXX by million ear, the Phase in chronic treated on foundation, an we throat is Lyra of medical of be which a underlying is for building we The platforms, leading problem X, As first patients to in X Lyra’s company a year – and effectiveness LYR-XXX estimated as build area United them XXX use The our States, roughly current and are for the rhinosinusitis, as nose intends XTreo company. and these

to now study results. Turning LANTERN our

the me Let were this very pleased we that say just experience and from trial. that with the patient data resulted

X,XXX including the at product CRS candidate. LANTERN treatment patients trial Phase several duration intended their to improvement for symptoms time X achieved control, a Our points show micrograms, in XX that weeks, treated significant statistically compared our with the

trial Phase Lyra to regulatory insight believes enable such, clear and program to to forward support LYR-XXX This of results X the FDA. also year. place meeting for As planned before to the path end pivotal first this that end provide of meeting an subject with half the move randomized the us clinical trial, is submission a blinded sufficient the data controlled this to of and of to take a

the Phase study LYR-XXX sufficient trial pivotal that package be pivotal application, single we complete for registration of will believe Following new our a under the XXXX. end XXX(b)(X) of anticipate to agreement design the initiating X on at drug the we

As and us arms improvement six months. with a chronic four effective XX X,XXX symptoms This the for weeks effective rhinosinusitis to We up XX statistically the both, LYR-XXX micrograms excited enrollment weeks, addition for be were three treatment SNOT-XX into the were pandemic. a other four confidence and significant from endpoints. reminder, microgram an dose and X,XXX cardinal planned for COVID-XX the symptoms in evaluated split nomadism, were of to to due LANTERN therapy was to in weeks see or patients at reduced the control, The XX up in cardinal XX of X,XXX to could four treatment curate scores. patients. trial This secondary the gives was completed to and micrograms,

both to at symptom in and cardinal control four relative improvement saw SNOT-XX time earlier we symptoms the Additionally, points scores. the

At in of patients curate, of dose the times weeks four XX. this by the was at XXX% dose used LANTERN by week the Another minimal key takeaway the trial. from and nomadism XX% the trial three the we important of the difference dose, SNOT-XX X Phase measured achieved score safety microgram demonstrating clinically as X,XXX our

set approved plan On the Based microgram symptom program. data, We believe of dose XX are the would a a LYR-XXX for X to and back relief for as LANTERN phase XX week move LYR-XXX forward and for data we who XXXX full over results observed the their a larger weeks, forward on to of proposed durable major XXth. this step surgery if endpoint the facing Combined support our on measure rapid at with option. present Phase Otolaryngology we patients the based deliver in next is care FDA April a treatment symptoms We CRS a to intend the pursue to trial Meetings, a the X Xth of pathway believe which pivotal COSM, April CRS, the trial Spring from being efficacy. held study from preferred primary clear cardinal of

Lyra's surgery and the and advance continuously LYR-XXX Importantly, is which the utilizes to confidence via an multiple XTreo that of and then these sustained to who administration. chronic to results for previously also is consistently platform, surgery program patients period require have to LYR-XXX this, LANTERN us over our the larger of ongoing proprietary disease see deliver Approximately a time drugs anatomy or study a support ENT utilize LANTERN XTreo LYR-XXX, directly, tissue will designed a matrix have XX% second who surgeries. gives had to single designed nasal platform of the rhinosinusitis undergone medical adapt management. of prior patients even patients. Because

The additional efficacy LANTERN the in plan either continuous bioavailability has successfully being to where we we positive programs now and see continues of results study, using and XTreo my to XTreo additional second showed believe the to LYR-XXX and be beyond development for local XXXX. for to delivery regard study would initiate as to believe study partnerships. delivery, microgram of the many can chronic LANTERN us the applications dose from to multiple tuneable indications as diseases Furthermore, versatility therapy delivered improve the provides deliver the XXXX treat with with enhance in months, potential we half which Given opportunities X internal drug Phase expansion CRS, that long-term period drug a six or safety. platform, which up XTreo Lyra the and

the his own share Dan allow to me to Kern, let the Officer Before LANTERN on Medical over Dr. I financials, the to discuss Chief perspective study. call our turn newly appointed

LYR-XXX. An I'm CMO. you, Thank from of Therapeutics Maria. Phase after very pleased data join appointment its I to company study X released the Lyra as accepted

with I see, clearly can you have voted feet. my quite As

to CRS a effective to therapy visit. As a product curative, is limitations impressive. to to practicing months for not these and I to symptom tissue I X demonstrated management often to with and first position with experience for to And mometasone a a for With Patients current as available patient clinical, paradigm nasal patients. be full new thus the trials. develop now I CRS data simple, potential has to of quarter. currently potential the whether maximum a to to of or of drug of appealing doubt such design patients would up can symptom for products limitations the prior of the the exerting patients worldwide. and eventual the six My or administration both is treatment achieve all ENT opportunity companies fourth FDA the prefer A hand call study will can to LANTERN study the single surgery. for delivering provides relate micrograms XXX with approval, potential medical effect offer have a quite benefit a unlike LYR-XXX CRS an to whether at to medications. ENT period has I Phase if and to the experience very will LANTERN treatment maximum regardless by is Mometasone physicians the the Lyra's directly had office polyps. continue that I LYR-XXX believe not the the and prolonged implant has LYR-XXX possible. financial that, only relief. patients is many summarize much require CRS, generated of Together, affected to eliminate forget the us had believe experience successful do, daily have they office a after Don, and even months so patients. have is well to change Don? avoid no for eliminate believe CRS, mometasone sinus Subject and therapeutic we to and compliance any physicians six full anti-inflammatory single prolonged years this the deliver to treat LYR-XXX need compliance believe no that candidate LYR-XXX working extended for effect There for What patients a CRS use results therapy is surgery after painful, pivotal surgery XXX to It treatments, time, in range treatment delivery. most outpatient offering relief from not continuously the be setting. often Currently, over otolaryngologist believe comprehensive

million, with you, XXXX. and The Total fourth the $X.X cash the our loss financial today expenses operating issued full. million, the equivalents net $XX.X quarter for results $X respectively. Thank quarter compared we million, year in of $XX.X for $XX.X with we for the Rob. million in Starting our cash the $X.X the fourth XX, balance, million were quarter as with and were release same fourth year ended and compared September period XXXX, outlines to million earnings and

call. So through go I this details will on the not

financial In to planned that of fund sufficient through has Lyra cash guidance, company believe into operations terms we XXXX. the

And of with shares XXXX turn December as Maria. Finally, million the to that, outstanding shares. were approximately XX, call Lyra's I'll back XX.X

months, LYR-XXX for for Thank the our In end of we and initiation study with milestones Phase prove the These Don. will several X include that of the you, the company. Phase coming X meeting have an pivotal LYR-XXX. for FDA

pandemic. our announcements study XX-day the full however, ease Before LANTERN application PK study, enroller the COVID U.S. deployment commented during study PK In of April. second have additional we will ongoing enrollment dataset completed in call. lead on patients an be presentation the of the PK subjects The U.S. in considering at and achievement our recently announced two LYR-XXXs in that, quarter, the January, analyst COSM LYR-XXX at from and and share first involving had with of in and will data to we of XX the based results itself you, which the

dedicated other include LYR-XXX to care Lyra sinus comments providing and for of ENT. likely Some satisfying, quick, And was sufferers. was continuum summary, remains In the to millions so fast the his for regarding painless his that be of learning administer. solutions and experience would administration of for curve across

needs clinical in with Our results is the we're pleased with well-aligned pipeline to-date. CRS and product the

enthusiasm our team their patients. at our impact share physician incredibly of for proud have the extraordinary think I'm I technology the for will built also Lyra. we've

accomplished the ingredients some went to under for just we have our We ago all we'd for we That take remarks much questions. a and today since concludes and have continue now prepared to we public so year like believe success.

thanks always, and support. continued Terry, line can ahead As open go for you your the interest up for and questions.

Instructions] first the Jefferies. Your from Chris from [Operator comes of line question Howerton

is line Your now open.

and you much congratulations so Thank progress. questions on Excellent. the taking for the

Chris. you, Thank

course. Great. of Yes,

So questions of just -- maybe for couple a me.

is, the to that's the focused has at market. I that discussed eventual to a results respect kind -- of but So, just past, and about the I can of you've shape question. With see buy housekeeping said to question. strategy another things topline been we have what reimbursement be receive the kind information able First you primarily And in how a we highlight one like thinking of, new you're time December? on that in build, the just CASM, that maybe relative kind at believe to on that willing you've from think presentation will question

So, we considering pharmacy is the the any whether you exploring if had progression. found to things build you or recently one guess, buy of question the physician very third the the you're not the view And some that one discussions of is disease evolved do in I things have interesting terms like, the route? still and the spoke of of question then idea was KOL we or halting specialty and

potentially progression, treatment guess, paradigm So, Kern the I'd starting could changing treatment? the so and comments be how of disease XXX and earlier, in curious that the eventual terms on be Dr. to I hear Thanks.

provide related can reimbursement the I Dr. on Corinne Kern question over start then -- and Thank for by with her CASM it Chris. comments to then, you, to turn -- and doctor--. to I'll the on thoughts

to April forward That week our CASM So, presenting mentioned will will at place, look of XX. take first I we April. results and as the that be

Chronic cardinal of Rhinosinusitis. We on will data presenting each be symptom

discharge, individually We've scores. As the cardinal each the And results facial a smell. we’ll reminder, the are four addition symptoms and -- the We’ll pertains SNOT-XX to also composite are to nasal of of and nasal score. those symptoms. symptoms. have it pain, symptoms four from obstruction, composite symptoms in the show shown Those cardinal composite the as three already of

our addition also In showing will to that, be we results.

objective have don't on MRI, be will we information. then, have And finally, we this that inflammation Our results be be assessed and and for so that MRI, pilots all showing using we'll new patients results. those patients both will also results pilots, by sharing

question your -- reimburse of on part second The was the

I’ll take second question.

Go Corinne. Yes. ahead,

strategy as and pharmacy the and that some will Corinne of are some specialty bill buy going buy specialty specialty as most model, our we appropriate hybrid as Yes. model, pharmacy. others network. Hi, enjoy have reimbursement there through benefits our a physicians the to Noyes. bill incorporates who continue will distribution through about development. the and are a well that is and to payers a who to But your plan Chris. a prefer course, now But require ease is model. of This question approach pharmacy of a There both, right we're going answer evaluate To progress will

we buy So model bill incorporates specialty and hybrid a distribution reimbursement having envision that and and pharmacy. both,

you. Clear. Thank Very Okay.

Corrinne, Rob. interject is I'll this -- now. Hi, enter

progression? device I arrest asked or this understood more disease asking? question might what correctly. that Is You you're less if your whether, about Whether

that is disease essentially, arrest alter yes, and mean, Yes. could you from sequelae do of nature the for the what progression a perspective? Like, the surgery, have treatment to are a they have question example? I even

FDA month that to where studies that sinusitis. would that's answer short will think beforehand think Again, one look with at assuredly period the that performed, -- the symptomatic, role And usually then diagnosed what case. be start if I we Well, that you is, that I they patients assuming be would the chronic get a the all limited and other, about have yes. six product, get that but there's for -- really get been and almost epidemiological approval yes,

a at they So maybe they're and there's suffering, year maybe haven't or months, been least when six diagnosed yet. so, fully

the think the disease, prevent very well again, I awareness get products there. to assuming that early physicians, and intervention of FDA progression market like that the because of product become this, like this approval, might we a aware the the come are patients, for out eventually and

that answer long short little And provided clarity. So more is, hopefully answer the yes. a

Yes. Maybe, of I that quick are if think like, trial Is follow that that long is -- don't in mind, follow whether term terms for think interesting a progressing be would or to up something you can you in clinical data guess, you that collect you I XXX patients surgical collect up, to setting? that if a there. something procedures? not received

You're ahead. like talking -- go

I Yes. way study, that implants we Maybe, had test our two that months followed removed. Phase were our the patients mention the and after six our then can X for a six Chris, in months

ongoing those an follow and to six for continue this months. additional We is patients

it's those tracking excellent patient's we – question, are and will symptoms. So an we

X oral steroids, can study have a I I their oral we is symptoms And to recur patients come that, off those tend think symptoms maybe Dr. pretty steroids is when do returned, thing the believe to speak sense will So when fully for when probably Kern Phase do that quickly. their one completed. with

do product a to Yes. that, mean, would the here, we'll get the we and I just I product market That's the but we're I morbidity. this months. the it, on is again, duration speculating used. think That's patients that bring progression well it – if correct. hopefully, to prevent a of imagine certainly longer intersect offer way surgical level six prevent And newer every would

And the we're that standpoint, from Phase going be X to Chris, of in patients no longer require a measurement the surgery. percent assessing

for outcome partly So asking maybe we'll is what which you're well. have an measure, as

an payers. surgery? And important does this will proxy preventing of we if of will that will require so time at benefit of assessment know entry? for So be our surgery have a for we patient be terms that still require surgery, in And they

Understood? Okay. you All right. Thank much. Great. very

Chris. you, Thank

Robert Hazlett the next of question line Your comes from BTIG. to

open. is Your now line

thanks. Hi, Bert all, upcoming on well? first Dr. BTIG. tweet the any quick study Hope in Just two My terms you of terms either question the that one a after more is or study; elements got two you're name or – the are of might in to be endpoints added might its pivotal primary symptom of from timing or or with there arrival cardinal with of or Kern, either study? that or the three want score, of secondary that? I've considered the any include

Sure.

Bert, So we a study. the very thanks – would successful for had We what X question. consider Phase

have three or we symptoms, exclusion would we cardinal as X. the using symptoms similar endpoint, going two are we very the -- So understanding in we announced FDA -- we what cardinal more inclusion the Phase be or to be mentioned, to are we'll cardinal the respect to cardinal is it symptoms With or using determined the prefer our our did we whether certainly keep symptoms. not yet will four that

at product it's so to I guide us that composite a X endpoint point and of months end six the as is will we appropriate be will planning be time month But duration is weeks, – for the mentioned, Phase product we will announce cardinal let our are data we most our use. it. and six be the wills able XX And primary which we symptoms. will after So meeting,

recent also for now wasn't that, when the approval there's Given of initiated precedents which there we antibodies, trial. the

we of again how we're to XXX also are XXX sort size that be stated other And have trial expecting to the about that's it. So thinking about that area previously the patients. we is

sense rapidly to study? Terrific. study, Thank enrollments US with X regard potential timing hear portend of with enrolled to and well that. Any great regard the mentioned color. what And that on enrollment case you just to you for just for might that Phase pivotal the it,

it our It will is meetings. study. really on is But at too early long provide we end to We that to it for say. the take perspective really how us too have after do certainly will this of early X enroll a Phase to point,

Okay. smaller a color mimic a just that's have and focus, opportunities will it it give XXX, on in on to or Phase or more maybe Thanks. the of of question study? scope design, if size this that with size, a And terms you little the regard then any just larger detail different a could additional X bit Will and – upcoming? LANTERN slightly timing

Sure.

This uncertain now dose. is it that LANTERN clearly that is we've that So anticipate be have aspect for matrix the made of to XXX another end interesting study, microgram considering. but study dose, XX are with the X,XXX include And a study two which going decision, LYR-XXX, moving we the designs we that approximately to for we're being will Prior actually the patients. we were that the also dose. forward we

So that XXX. from different will be

micrograms from We situation. our see candidates it So design two doses, them which of XXX XTreo derisk. have deliver two X,XXX this We both platform. both as designed, and actually and have in the of very one

the going this So to XXXX. into study in half on X target we're right Phase start the second of we're and

to more with the the and the regard hands got broadly, color. XTreo anything should Terrific. development to with clearly full additional we in regard XXX, And platform just to going me. there, regard to additional XTreo expect Appreciate you've – for With mid-term one the on near with opportunities? more but the your XXX

within lends the other tight the make ear fit definitely spaces very the in to places small we to platform can platform other XTreo the the treatment the itself areas, many of or that agree sinus. do We into

started. right We now as focused getting LYR-XXX very those you and said, are, on trials XXX and

meeting around that with work do other we and at in really research point physicians. the is market this the areas However,

from programs. work So, in we're clinical away still ways those a

so I progress. much. Congratulations Okay, appreciate you it. on the all terrific. Thank

Thank you, Bert.

of from comes the Verma Bank from question next of Your line Ash America.

now is line Your open.

Ash. there. on This questions. our is taking Congrats Hi, for Thanks the progress.

had of So, a I questions. couple

just was Can this for on what what first to The the Second of trial? situation? pertains this the you the just like to be us you the the is in consider the pharmacokinetics remind on a results, question one design like study. And win guidance. financial expectation would

think guidance I why you And I then the had what year this in around cash And gave question not flow last the schedule financial year, around for $XX agenda for did mentioned, you that the points and do chose you specific -- million you for certainly that, to schedule similar not FDA the spend think million finishing XXXX that was $XX a third if meeting, I have you year? that much, meeting? of to guide it? that still are need the have that this just discussion around you some or curious is

you, Ash. Thank

Yes.

XX was patients it on, fall. started fall study at the at -- within were we study of patients XX goal start PK those all and will in And the able we going to XX PK micrograms. the the We design. the the all and I we patients. enroll and the did pandemic micrograms So, X,XXX X,XXX enrolled the while enroll with to the were was

Phase to of furoate we NDA. to as mometasone the us sites that execute were product allowed that the that draws the a this in and to taking do we US patients And blood, that would for going some the experience get in going the we study. of is XXX(b)(X) blood need well level -- us -- and study required have do what US design to in the is thrilled trial. to that and experience serve able it The the be we're were we in from determining we're characterization X that So, these

will be XXXX. the from And that is study still study quarter in second that ongoing. announcing results We of

Yes.

take question question. and your Don then your third Let can second take me maybe

that we're feedback. second And them. in study we've be to at of I been FDA. FDA until meeting in quarter get is to had the contact for the that the plans So, goal Again, conversations end the the for and meeting have FDA that tell plans meeting at as -- with Again, review results our the and will this and Phase then can extensive -- to past. planned with LANTERN we point we that what before propose the having FDA’s is with X the our you

continuing of we're Phase we'll the So -- be meeting. end Don? at those X

Great.

So, Ash join If is your is understood this you XXXX correct? that Don. us we could correctly, Glad for question why you guidance asking I giving were weren't specifically, today.

right. That's Yeah.

fell guidance, this of And of on really a we took XX/XX, or for X Okay. Yeah. to side XXX. really doing starting the on it look X little a When probably side We're we're giving was XX/XX. felt it other a at transfer. less fell Phase meaningful Ash, XXX, was Phase for it tech we as externally it whether

meaningful end that you cash it give all It programs to So those saying take was year would that that yardstick if span was guidance us will. thought total of we simple. into XXXX and resources on a our more a

much. so Okay, you got Thank Great. it.

Ash. you, Thank

Our Instructions] Lugo Tim from [Operator the line from question comes William Blair. of last

now is line open. Your

what six any you the covered how change to the to the And, be were consistent of I joining cardinal as for others, in financial maybe broadly, efficacy symptoms? And like really the question. a just Thanks of month will ENT this symptoms know taking Were across about than more on release. in deviates hear the this treatment results LANTERN? the field. appreciate upcoming cardinal then area any sounds the just analysts team? that And I the around But want also the the will Dr. can there symptoms much But call. really from of discuss of the brought Kern, Lyra it individual you data you your around or thoughts

ahead? You to want go me

I don't first Why then and symptoms, Rob, with go the you the take Yeah. cardinal can one. next

So, we cardinal that composite. symptoms four the and have shared

about so four a we such at is what dose four the dramatic at change the weeks, comprised points and cardinal and of of it's symptoms, over see of effect in points those five nearly XX And high weeks, we four X.X see a it because symptoms.

So a significant what expect is those here. each of symptoms effect is would you that having

would also an effect and improvement be earlier, the cardinal those certainly when non-polyp with But showing we each you full of I So, we are both patients, will share an as those. expect, smell. sometimes as can't in symptoms, as had have seeing you patients. And then, polyp disease defined are patients we our of on the Non-polyp that data we do since our now. is mentioned less release.

will we results nasal discharge effect pressure. nasal to sharing with addition in pain and congestion, smell be those and facial their also so, you, the on And

And and you. your brought to thank what Kern, Interesting, join thoughts you team around LANTERN? maybe Dr. the

to action. the game about. six – with this every was things too, longer is months. I I Pi been problems, years. not a basis. for a that a that been from way change really this think much to is Well, with with we it's National really I market. of many I've people that's got talked with of potential the to expensive But, the – involved and that two practice months take product care trial but that And months, lot that many has an of that the It's companies maybe brought I everyday on RESOLVE SINUVA I product life. sinus XX duration as biologics, has mean, And way it's runny noses – the boring is my changer. in But Six usually

and laboratory this while work to knew here space. involved basic clinical their the out getting me opportunity now, here with move was with. very plus to space of and so, team XX And they I a for I And the work thought scientists. to pleasant were an I

combined make research this We an care bring take a country entire have difference. opportunity than to for product actually I patient practical thought money NIH that more a Northwestern, been in the could that really to experience And sinusitis. was and it laboratory

So, of that's why kind here. I'm

comes I us CRS as noses appreciate sufferer, dedication with all pain, that runny you. Kern, of that Dr. and Well, facial those with your of and along care. Thank a to

Thank you.

conference the now this would Palasis. time. am to no like further back Maria turn I at showing I to questions

in requests Healthcare Terry. to Thank May, With today's would we thank your rest you, for that, virtually In call. of to Have conference, participating and the I meetings you a welcome great Bank plan of all interim. America like for we attend in day. the them

you. Thank

conference call. all participation, gentlemen, and a wonderful have this Thank concludes and your day. for you today's Ladies

disconnect. may You all